Journal article
Phase II Study of Imatinib in Patients with Small Cell Lung Cancer
BE Johnson, T Fischer, B Fischer, D Dunlop, D Rischin, S Silberman, M Ortu Kowalski, D Sayles, S Dimitrijevic, C Fletcher, J Hornick, R Salgia, T Le Chevalier
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2003
Abstract
Purpose: The purpose of our study was to assess the objective response to imatinib administered to patients with small cell lung cancer (SCLC). Experimental Design: Eligible patients were those with SCLC who either had chemotherapy-naive extensive-stage or had SCLC in a sensitive relapse. Patients enrolled on the trial were treated with 600 mg of imatinib daily. The response was assessed using Southwest Oncology Group (SWOG) criteria after 3 and 6 weeks. Tumor specimens were examined by immunohistochemistry for the KIT receptor. Results: Nineteen patients with SCLC entered on the study, including 16 men and 3 women. Nine patients had previously untreated extensive-stage disease and 10 patien..
View full abstract